Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histology confirms colonic adenocarcinoma.~* The distance from the lower edge of the tumor to the anal edge is greater than or equal to 15cm (from sigmoid colon to ileocecal region)~* Preoperative staging (Satisfying any one out of four conditions below)~  1. Tumor infiltrates through the intestinal wall and adheres to tissues and organs around the colon(T4b), imaging assesses that R0 resection is unachievable.~ 2. Pericolonic lymph node involvement is closely adjacent to the large abdominal vessels, imaging assesses that lymphadenectomy is difficult.~ 3. Surgical exploration indicates that R0 resection is not achievable.~ 4. In initial diagnosis, surgeon evaluates the need for extensive multi-organ combined resection and expected to damage the organs, which would seriously affect the postoperative quality of life.~* No obvious signs of intestinal obstruction, or obstruction has been relieved after proximal enterostomy.~* Preoperative CT/MRI/PET-CT has ruled out distant metastasis.~* Blood and biochemical indexes achieve standard (Satisfying all three conditions below):~  1. Routine blood test: WBC\>4000/mm3; PLT\>100000/mm3; Hb\>6g/dl.~ 2. Liver function: SGOT, SGPT and Bilirubin are less than or equal to 1.5 times normal upper limit.~ 3. Renal function: Creatinine is less than or equal to 1.5 times normal upper limit.~Exclusion Criteria:~* History: Has colon surgery history; Received chemotherapy or biotherapy in the past 5 years; Received radiotherapy in treatment field.~* Infectious disease: HIV infection history; Active phase chronic hepatitis B or hepatitis C (high copies of virus DNA); Other serious active clinical infection.~* Diagnosed as stage I colon cancer.~* Extraperitoneal distant metastasis is positive in pre-operative stage.~* Dyscrasia or organ decompensation.~* Received radiation therapy in abdominal or pelvic regions.~* Multiple primary cancer.~* Epileptic seizures requiring medical treatment.~* Other malignant tumor history in the past 5 years (except endocervical cancer in situ or skin basal cell carcinoma which had been cured)~* Chronic inflammatory colorectal disease, unrelieved ileus.~* Drug abuse, has medical, psychological or social condition that might affect research results.~* Allergic to research-related drugs.~* Any unstable situation that might endanger patient's safety or compliance.~* Pregnant, lactating woman patient or fertile but lacks adequate contraceptives.~* Refuses to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant chemoradiotherapy group (Type: EXPERIMENTAL): Neoadjuvant chemoradiotherapy（XELOX \* 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
- Neoadjuvant chemotherapy group (Type: OTHER): Arm Type: control. Neoadjuvant chemotherapy（XELOX \* 4）→ Surgery (if possible) → post-surgery chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility